查詢結果分析
相關文獻
- 不同年齡癌症病人之Vancomycin藥動學
- A Patient of Primary Hyperparathyroidism with Full-Blown Bone Changes Simulating Malignancy
- 減少腹腔鏡治療癌症病患後穿刺孔復發的方法
- 妊娠併發卵巢惡性腫瘤暨先前腫瘤囊腫經皮穿刺抽吸之結果與預後--病例報告
- Malignancy Following Renal Transplantation
- The Effects of Arginase on Neoplasm (1):The Role of Arginase in the Immunosuppressive Effects of Extract from Gastric Cancer
- 下眼瞼惡性腫瘤之處置
- 冷凍手術在肝臟惡性腫瘤的應用
- Enterovesical Fistula: Experiences with 41 Cases in 12 Years
- 核子醫學對惡性腫瘤的臨床應用
頁籤選單縮合
題 名 | 不同年齡癌症病人之Vancomycin藥動學=Vancomycin Pharmacokinetics in Cancer Patients among Different Age Groups |
---|---|
作 者 | 葉春蘭; 陳筱伶; 朱麗鈴; 王慧瑜; | 書刊名 | 藥學雜誌 |
卷 期 | 29:1=114 2013.03[民102.03] |
頁 次 | 頁71-75 |
分類號 | 418.281 |
關鍵詞 | 惡性腫瘤; 藥物動力學參數; Vancomycin; |
語 文 | 中文(Chinese) |
中文摘要 | 癌症 (惡性腫瘤) 病人使用 vancomycin 因分佈體積和清除率的增加,因而應使用較高劑量,但對於不同年齡族群的病人是否皆有相同結果值得探討,因此本研究回溯性蒐集某醫學中心使用 vancomycin 之惡性腫瘤與非惡性腫瘤病人,並將其年齡區分為65歲以下及65歲以上之族群,分析其分佈體積、清除率和半衰期等藥物動力學參數,是否因年紀不同而有差異。 本研究共蒐集116位病人,其中惡性腫瘤病人52位,非惡性腫瘤病人64位,這些病人進一步區分為65歲以下和65歲以上族群分別為78位和38位,其中65歲以下族群惡性腫瘤病人35位,非惡性腫瘤病人43位;65歲以上族群惡性腫瘤病人17位,非惡性腫瘤病人21位,分析其藥物動力學參數,發現65歲以下族群之平均分佈體積和清除率惡性腫瘤病人高於非惡性腫瘤病人,並具有統計上差異 (P<0.05);然而65歲以上族群平均分佈體積惡性腫瘤病人高於非惡性腫瘤病人 (P<0.05),而平均清除率兩者並無統計上差異;另外在半衰期方面,各個年齡層,不論是否為惡性腫瘤,半衰期均無統計上差異,此初步結果顯示惡性腫瘤病人尤其是65歲以下病人,因分佈體積和清除率比同年齡層之非惡性腫瘤病人增加,因此如欲達到和非惡性腫瘤病人相同的血中濃度,應使用較高劑量;而65歲以上惡性腫瘤病人,初步結果分佈體積有統計上差異,而清除率兩者無統計上差異,因蒐集人數少,因此有待進一步探討。 |
英文摘要 | According to the previous studies, dose adjustments for vancomycin among cancer patients are necessary because of the increased volume of distribution (Vd) and clearance (CL). However, far too little attention has been paid to different age groups. In this retrospective study, subjects were collected from vancomycin users and classified into 2 group: age ≥ 65 and age < 65. Within both groups, patients were classified again by cancer diagnosis (cancer group and non-cancer group). The individual pharmacokinetic parameters (Vd, CL and half-life) were calculated and compared between cancer and non-cancer patients in different age groups. A total of 116 patients were recruited in this study, 38 patients were older than or equal to 65 and 78 patients were younger than 65. In the group of age ≥ 65, included 17 cancer patients and 21 non-cancer patients. On the other hand, there were 35 cancer patients and 43 non-cancer patients in the group of age < 65. Based on the results of pharmacokinetic parameters, the mean Vd and CL of cancer patients were higher significantly than non-cancer patients in the group of age < 65. Besides, the mean Vd of cancer patients was significantly higher than non-cancer patients in the group of age ≥ 65. However, the mean CL was no statistical difference between cancer and non-cancer patients in the group of age ≥ 65. Furthermore, the average of half-life was no statistical difference between cancer and non-cancer patients in both age groups. Based on the above results, the dosage for cancer patients whose age less than 65 should be increased in order to achieve the same therapeutic effect. |
本系統中英文摘要資訊取自各篇刊載內容。